Disclosures for "The Radiant Light: Efficacy and Safety of Oveporexton (TAK-861), an Oral Orexin Receptor Two Agonist for the Treatment of Narcolepsy Type One"
-
Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for idorsia. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for JAZZ. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avadel. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alkermes. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Centessa. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bioprojet. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Harmony Bioscience.
-
Dr. Antczak has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Edocera Sp. z o.o. . Dr. Antczak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lion Communication oddzial MSL.
-
The institution of Dr. Buntinx has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for J&J. The institution of Dr. Buntinx has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli-Lilly. The institution of Dr. Buntinx has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for ANIMA Research. Dr. Buntinx has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for ANIMA Medical. Dr. Buntinx has stock in ANIMA Research bv. Dr. Buntinx has stock in ANIMA Medical bv. Dr. Buntinx has stock in Linde Buntinx bv. Dr. Buntinx has stock in Elise Buntinx bv. Dr. Buntinx has stock in ANIMA Clinical. Dr. Buntinx has stock in ANeuroTech bv. Dr. Buntinx has stock in Integra Invest. Dr. Buntinx has stock in Integra bv. Dr. Buntinx has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Del Río Villegas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TAKEDA. Dr. Del Río Villegas has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ALKERMES.
-
Prof. Hong has nothing to disclose.
-
Dr. Sivam has nothing to disclose.
-
Shuqin Zhan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for akeda Pharmaceuticals. Shuqin Zhan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Co., Ltd. Shuqin Zhan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Yes Biotech. The institution of Shuqin Zhan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Simcere Pharmaceutical Group. The institution of Shuqin Zhan has received research support from National Natural Science Foundation of China (NSFC). The institution of Shuqin Zhan has received research support from Ministry of Science and Technology of China. Shuqin Zhan has a non-compensated relationship as a Vice President with Chinese Sleep Research Society (CSRS) that is relevant to AAN interests or activities. Shuqin Zhan has a non-compensated relationship as a reviewer with National Natural Science Foundation of China (NSFC) that is relevant to AAN interests or activities.
-
Elena Koundourakis has nothing to disclose.
-
Ms. Neuwirth has received personal compensation for serving as an employee of Takeda. Ms. Neuwirth has stock in Takeda.
-
Dr. Olsson has received personal compensation for serving as an employee of Takeda. Dr. Olsson has stock in Takeda.
-
Dr. Sheikh has received personal compensation for serving as an employee of Takeda.
-
Dr. Von Rosenstiel has received personal compensation for serving as an employee of Takeda. Dr. Von Rosenstiel has stock in Takeda.
-
Dr. Yao has received personal compensation for serving as an employee of Takeda Pharmaceuticals.
-
Dr. Cai has received personal compensation for serving as an employee of Takeda.
-
The institution of Dr. Plazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TAKEDA. The institution of Dr. Plazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOPROJET. The institution of Dr. Plazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for JAZZ. The institution of Dr. Plazzi has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for OREXIA. The institution of Dr. Plazzi has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for OREXIA/CENTESSA.